IP Decisions
Subject | [Patent]Patent Court Decision, 2016Heo4733, decided May 12, 2017 (Sorafenib Tosylate Case) | ||||
---|---|---|---|---|---|
Writer | Á¤º¸°ø°³´ã´çÀÚ | Date | 2018.02.12 | Hit | 411 |
Attachments | 2017_[1] 2016Heo4733.pdf | ||||
Patent Court Decision, 2016Heo4733, decided May 12, 2017 (Sorafenib Tosylate Case)
Invention Claim 1 in this case and Prior art 1 were activators which were common in the fact that they were pharmaceutical compositions to treat overgrowth disorders including cancer which included refined insulin containing sorafenib tosylate acid but they differed in the sense that Invention Claim 1 in this case designated inclusion of at least 55% sorafenib tosylate in terms of weight composition while Prior art 1 did not designate the content of sorafenib tosylate in 50mg tablet which made it impossible to determine the weight ratio of sorafenib tosylate in the entire composition. But such designation of value above for Invention Claim 1 in this case can be easily conceived from prior arts by a person with ordinary skills and the significance of such effect cannot be recognized which denies the inventiveness for Invention Claim 1 in this case.
|
Previous | [Patent]Patent Court Decision, 2016Heo7695, d... |
---|---|
Next | [Trademark] Patent Court Decision, 2015Heo399... |